Todos and Amarantus JV Announces Full Enrollment for Clinical Trial of LymPro Alzheimer’s Blood Test Relationship with Amyloid PET
November 14, 2019 11:02 ET
|
Todos Medical Ltd.
Topline results expected before the end of Q1/2020 REHOVOT, Israel and NEW YORK, Nov. 14, 2019 (GLOBE NEWSWIRE) -- Todos Medical Ltd. (OTCQB: TOMDF), a clinical-stage in-vitro diagnostics company...
Todos Medical to Appoint Dr. Paula Trzepacz As Chief Medical Officer And Files New Patent Application
July 12, 2019 11:05 ET
|
Todos Medical Ltd.
Joint venture Breakthrough Diagnostics files new patent application covering Alzheimer’s blood diagnostic LymPro Test clinical correlation with amyloid PET imagingPreliminary Data on LymPro vs....
Todos and Amarantus Announce Completion of LymPro PET 1 Study by Leipzig University for Alzheimer’s Blood Diagnostic LymPro Test 2.0
April 08, 2019 07:30 ET
|
Todos Medical Ltd.; Amarantus Bioscience Holdings, Inc.
REHOVOT, Israel and NEW YORK, April 08, 2019 (GLOBE NEWSWIRE) -- Todos Medical Ltd. (OTCQB: TOMDF), a clinical-stage in-vitro diagnostics company focused on the development of blood tests for the...
Todos Medical Enters into Joint Venture Agreement with Amarantus to develop Alzheimer’s Blood Diagnostic LymPro Test 2.0
December 03, 2018 08:30 ET
|
Todos Medical Ltd.
REHOVOT, Israel and NEW YORK, Dec. 03, 2018 (GLOBE NEWSWIRE) -- Todos Medical Ltd. (OTCQB: TOMDF), a clinical-stage in-vitro diagnostics company focused on the development of blood tests for the...
Amarantus Subsidiary MANF Therapeutics Receives Notice of Allowance from U.S. Patent & Trademark Office Covering MANF Treatment of Diabetes
December 11, 2017 08:00 ET
|
Amarantus Bioscience Holdings, Inc.
Allowed claims include the treatment of Type 1 and Type 2 DiabetesOnce issued, patents extend exclusivity for MANF in the US into 2032 SAN FRANCISCO, Dec. 11, 2017 (GLOBE NEWSWIRE) -- Amarantus...
Amarantus BioSciences' CEO Gerald Commissiong to Appear on the Big Biz Radio Show
March 16, 2012 10:13 ET
|
Amarantus BioSciences
SUNNYVALE, Calif., March 16, 2012 (GLOBE NEWSWIRE) -- Amarantus BioSciences, Inc. (OTCBB:AMBS), a biotechnology company developing MANF, a first-in-class disease-modifying therapeutic protein, today...